Carolina Gracitelli, None;
Linda Zangwill, Carl Zeiss Meditec Inc. (F), Heidelberg Engineering GmbH (F), Optovue Inc. (F);
Alberto Diniz-Filho, None;
Ricardo Abe, None;
Robert Weinreb, Alcon Laboratories Inc (C), Allergan (C), Amateck (C), Bausch & Lomb (C), Carl Zeiss Meditec (C), Carl Zeiss Meditec (R), Forsight (C), Genentech (R), Heidelberg Engineering (R), Konan (R), National Eye Institute (R), Neurovision (R), Optovue (R), Quark (R), Reichert (R), Tomey (R), Topcon (C), Topcon (R), Valeant (C);
Christopher Girkin, Carl Zeiss Meditech, Inc. (F), EyeSight Foundation of Alabama (F), Heidelberg Engineering, GmbH (F), National Eye Institute (F), Research to Prevent Blindness (F), SOLX (F);
Jeffrey Liebmann, Alcon, Inc. (C), Allergan, Inc. (C), Bausch & Lomb, Inc. (C), Bausch & Lomb, Inc. (F), Carl Zeiss Meditech, Inc. (C), Carl Zeiss Meditech, Inc. (F), Diopysis, Inc. (C), Diopysis, Inc. (E), Diopysis, Inc. (F), Heidelberg Engineering Inc (C), Heidelberg Engineering Inc (F), Merz Phamaceuticals (C), National Eye Institute (F), New York Glaucoma Research Institute (F), Optovue, Inc. (F), Quark Pharmaceuticals (C), Reichert, Inc. (C), Reichert, Inc. (F), Sensimed, Inc. (C), SOLX, Inc. (F), SOLX, Inc. (E), Sustained Nano System (E), Sustained Nano System (P), Topcon, Inc. (F), Valeant Pharmacetiicals (C);
Felipe Medeiros, Alcon Laboratories Inc (R), Alcon Laboratories Inc (F), Allergan Inc (F), Allergan Inc (R), Allergan Inc (C), Bausch & Lomb (F), Carl Zeiss Meditec Inc (F), Carl Zeiss Meditec Inc (R), Carl Zeiss Meditec Inc (C), Heidelberg Engineering Inc (F), Merck Inc (F), National Eye Institute (F), Novartis (C), Reichert Inc (R), Reichert Inc (F), Sensimed (F), Topcon Inc (F)